Material Event (Form 8-K)

Item 8.01 Other Events.

As previously reported, on November 25, 2025, BiomX Inc. ("BiomX" or the "Company") announced that an independent Data Monitoring Committee ("DMC") completed a safety review and recommended continuation of the Company's Phase 2b clinical trial (the "Study") that is designed to test the Company's drug candidate BX004 ("BX004") in treating Cystic Fibrosis ("CF") with an adjusted dosing regimen.

On December 8, 2025, BiomX announced its discontinuation of the ongoing Study with CF associated with chronic Pseudomonas aeruginosa infections. After evaluating the projected timelines and resources required to proceed with an alternative dosing strategy as was recommended by the DMC, the Company determined that such requirements were beyond the Company's available resources, leading to the decision to discontinue the program. The Company is also taking cost-cutting measures, including a significant reduction of its workforce. Subject to availability of sufficient financial and other resources, BiomX will now focus on advancing its bacteriophage-based therapeutics, particularly BX011 for diabetic foot infections. Simultaneously, the Company is reviewing other strategic alternatives.